| CHB-ACLF (HBeAg positive, N = 6) | CHB-ACLF (HBeAg negative, N = 6) | Treatment naïve CHB | |||
---|---|---|---|---|---|---|
Immune tolerance (NÂ =Â 2) | Immune active (NÂ =Â 9) | Inactive (NÂ =Â 5) | HBeAg negative hepatitis (NÂ =Â 11) | |||
Median age (range)/# male | 49 (21–64)/6 | 52 (26–57)/5 | 28 (20–35)/1 | 47 (23–50)/2 | 52 (45–61)/1 | 43 (36–57)/11 |
Ethnicity | 6 Chinese | 6 Chinese | 1 Chinese; 1 Eastern European | 6 Chinese; 1 Tibetian; 1 Vietnam; 1 Indonesia | 3 East- Europe; 1 Korean; 1 African | 6 Chinese; 1 Lebanese; 2 Vietnam; 1 Fillipino; 1 Egyptian |
Median HBV DNA (rang, log IU/mL) | 5.7 (4.3–7.3) | 3.7 (2.2–5.9) | 8.5 (8.0–8.6) | 8.0 (4.5–9.0) | 3.1 (UD-3.6) | 4.3 (2.9–6.2) |
Median ALT (rang, U/L) | 562 (23–1584) | 112 (48–2347) | 37 (20–33) | 86 (27–353) | 25 (14–48) | 48 (20–106) |
# HBeAg negative patients | 0/6 | 6/6 | 0/2 | 0/9 | 5/5 | 11/11 |
Genotype | 1 B; 3 C; 2 unknown | 2 B; 2 C; 2 unknown | 1 B, 1 D | 3 B, 5 C, 1 D | 1 A, 1 B, 1 C, 1 D, 1 E | 4 B, 4 C, 2 D, 1E |
Median HBsAg (rang, log IU/mL3) | unknown | unknown | unknown | 4.0 (2–9.8) | 3.9 (2.7–5.1) | 3.5 (1.6–9.1) |
# Liver fibrosis | 3/6 | 5/6 | 0/2 | 3/9 | 0/5 | 5/11 |
# History of NA treatment | 1 LAM | 4 LAM | N/A | NA | N/A | NA |
# Surviral (4Â weeks after onset) | 2/6 | 2/6 | All alive | All alive | All alive | All alive |